L.M. Kohn & Company’s AbbVie ABBV Stock Holding History

L.M. Kohn & Company’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$935K	Sell	4,037 -3,158	-44%	-$643K	1.12%	24
2025 Q2	$1.34M	Sell	7,195 -4,705	-40%	-$874K	0.36%	48
2025 Q1	$2.49M	Sell	11,900 -646	-5%	-$126K	0.65%	26
2024 Q4	$2.23M	Sell	12,546 -529	-4%	-$97.3K	0.58%	33
2024 Q3	$2.58M	Sell	13,075 -234	-2%	-$43.7K	0.65%	27
2024 Q2	$2.28M	Sell	13,309 -231	-2%	-$38.3K	0.62%	25
2024 Q1	$2.47M	Sell	13,540 -562	-4%	-$96.9K	0.69%	23
2023 Q4	$2.19M	Buy	14,102 +524	+4%	+$76.4K	0.7%	22
2023 Q3	$2.02M	Sell	13,578 -442	-3%	-$64.9K	0.74%	21
2023 Q2	$1.89M	Sell	14,020 -16	-0.1%	-$2.35K	0.71%	24
2023 Q1	$2.24M	Sell	14,036 -391	-3%	-$59.8K	0.93%	19
2022 Q4	$2.33M	Sell	14,427 -218	-1%	-$33.4K	1.09%	17
2022 Q3	$1.97M	Sell	14,645 -1,217	-8%	-$175K	0.96%	19
2022 Q2	$2.43M	Buy	15,862 +1,102	+7%	+$168K	1.14%	16
2022 Q1	$2.39M	Buy	+14,760	New	+$2.14M	0.92%	17

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

L.M. Kohn & Company's ABBV Position: Q3 2025 in Review

L.M. Kohn & Company reduced its AbbVie (ABBV) stake by 44% in Q3 2025, selling an estimated $643K and leaving 4,037 shares worth $935K. The position accounts for 1.12% of the portfolio, ranked #24.

L.M. Kohn & Company first reported a position in ABBV in Q1 2022 and has held it in 15 quarters since. The position peaked at $2.58M in Q3 2024. 3,915 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

L.M. Kohn & Company held 4,037 shares of AbbVie worth $935K as of Q3 2025.
L.M. Kohn & Company sold 3,158 AbbVie shares in Q3 2025, an estimated $643K.
AbbVie made up 1.12% of L.M. Kohn & Company's portfolio in Q3 2025, its #24 holding.
L.M. Kohn & Company first reported a position in AbbVie in Q1 2022 and has held it in 15 quarters since.
L.M. Kohn & Company's AbbVie position peaked at $2.58M in Q3 2024.
3,915 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on L.M. Kohn & Company's 13F filing for Q3 2025, filed 4 Nov 2025.